The Humble Hang

The Humble Hang

By Shuchi Rana & RItesh PatelBusinessHealth & Fitness
Download on the App Store

All The Humble Hang episodes

  • She’s Building a Research Lab in Space. Her Real Target Is Healthcare on Earth -A conversation with Savi Glowe, BioAstra
    In 2016, Scott Kelly spent a year in space while his twin brother Mark stayed home. The study that followed showed how space changes the human body at the molecular level.

    BioAstra grew out of that work. Savi Glowe is CEO and co-founder of BioAstra, a nonprofit building the medical systems humans will need in deep space. She started out as a college dropout and massage therapist, then studied Shakespeare and anthropology, and later worked as a data scientist at Mount Sinai.

    Her argument is simple. Anything that works in space has to be small, rugged, self-powered, and autonomous. Medicine built under those limits can reach people on Earth whom today’s healthcare system cannot. In this episode of The Humble Hang, Savi tells us about:
    • Collecting 1,000+ microbial samples at Bikini Atoll, the old nuclear test site, to look for genes that resist radiation
    • Why “nobody was ever cured by a PDF” became her team’s mantra
    • HERO, BioAstra’s research program on humans in extreme environments
    • Why investors chase defense and orbital data centers, and why she believes biology is what will sustain the space economy
    • How a nonprofit earns revenue through CRO services, spinouts and a joint raise with partners
    • Whether aliens exist, and why we still send humans instead of robots
    Follow BioAstra on LinkedIn. Early-career researchers can apply for its fellowship. Health systems, universities, and pharma teams can partner on its human data from space.

    A podcast from Humble Ventures
    36 min
  • 1,000 Americans die of cancer every day who don’t have to. That number comes from Ben Freeberg, founder of Oncology Ventures.
    Ben Freeberg joined Shuchi Rana and me on our latest episode.

    Saving those lives doesn’t need a new drug. It needs earlier detection, better management of side effects, and getting the right patient onto the right treatment that already exists.

    Ben speaks from experience. He was diagnosed with cancer at 24. Today he manages $95M across two funds. His investors treat one in three cancer patients in the US.His goal is to make cancer a chronic disease. Someday you should be able to say, “I had cancer in December. In January we went skiing.”

    Oh, and he also does stand-up comedy. Some of his best material is about cancer. He’ll tell you why.

    This one is about 33 minutes, but worth every one.

    A podcast from Humble Ventures
    34 min
  • Value-Based Care Explained: Why It's Still "Fee for Service 2.0" with Nzinga Lowe
    Value-based care pays doctors for keeping patients healthy, not for the number of visits.

    It has been around since the early 2000s. Yet most patients have never heard of it, and many physicians don't know how to make it work.

    Nzinga Lowe, founder of Pygmalion Health, explains why. She began as a donor and transplant coordinator in Florida. She went on to build quality programs for diabetic eye screening and grow medical groups across the Southeast, the East Coast and the West Coast. Today she advises physicians, health systems and startups on value-based care, longevity and precision health.

    A podcast from Humble Ventures
    36 min
  • Why Digital Health Startups Miss Their Revenue Targets
    Most digital health founders expect an academic medical center to sign within six months. The data says 15 to 30 months. That gap is where revenue projections go to die.

    Kirk Barnes has sold in healthcare for over 25 years. He was employee #126 at Takeda Pharmaceuticals in the U.S. He sold for Johnson & Johnson and for the biotech business that is now part of Pfizer. He built the first health tech program in the 40-year history of Georgia Tech's incubator.

    Today he runs the Digital Health Sales Institute, which teaches founders how to sell to hospitals, pharma, payers, and the VA.

    In this episode of The Humble Hang, we talk with Kirk about what startups get wrong about healthcare sales, and how to fix it. You will learn:
    • Why your first sales hire should not be a VP of Sales. Kirk calls it the half-million-dollar mistake.
    • How to tell a suspect from a prospect, and why FQHCs and independent groups may pay the bills before AMCs do
    • Why a typical 12-month healthcare deal involves only five or six hours face to face, and what to do with the rest of the time
    • How to build internal champions who will spend their political capital on you
    • Why the decision about your deal will be made when you are not in the room


    A podcast from Humble Ventures
    33 min
  • Making Healthcare Autonomous: Ganesh Padmanabhan on AI, Token Economics, and the Real ROI
    Ganesh Padmanabhan came out of COVID with no healthcare background and one question: what's the point of AI if it just sells more sneakers? Four years later, his company, Autonomize, powers four of the five largest health enterprises in America.

    His idea was simple. Healthcare doesn't lack solutions. It drowns in point solutions. Nobody built the plumbing. So Autonomize built an AI infrastructure layer instead of another app — one system that handles prior authorization, care gaps, and payment integrity for payers, providers, and life sciences companies alike.

    The numbers are the story. Cigna now makes certain coverage decisions fifty times faster. Token costs have jumped 10 to 20x in a year, so Autonomize published its own research, RLM-Opt, to cut that spend. And a stat that stopped us cold: seventy percent of older adults would rather get a text than a phone call. Every dollar poured into voice AI for seniors may be pointed the wrong way.

    A podcast from Humble Ventures
    38 min
  • Provenance First, AI Second - Dr. MaryAnne Rizk on The Humble Hang
    Every pharma company wants to be "AI-first." Few know what that means.

    Dr. MaryAnne Rizk does. She started as an engineer in quality assurance at Merck during Y2K. She went on to Oracle, IQVIA, Medable, and the applied AI science team at AWS.

    Today she advises biopharma companies and startups on how to put AI to work without losing the rigor that regulated science demands. We ask her where the industry has made real progress, and where it has not.

    You will learn:
    Why "provenance first" beats "AI-first"
    The four trade-offs every biopharma leader must weigh: speed vs. rigor, exploration vs. execution, science vs. market, build vs. buy
    How to move AI from pilot to production
    Why incentives for AI must start in the C-suite
    The Amazon "working backwards" exercise, and why just because you can does not mean you should

    It is not man versus machine. It is man and machine.

    A podcast from Humble Ventures
    44 min
  • Beyond the Hype: Digital Health Is Growing Up
    In our latest episode of The Humble Hang, we sat down with Julien de Salaberry, Founder and CEO of Galen Growth, and Sara Schmachtenberg, who leads the company's research and thought leadership.

    For more than a decade, Galen Growth has been tracking the evolution of digital health through one of the industry's most extensive proprietary datasets, giving Julien and Sara a unique vantage point into not only where capital is flowing, but where healthcare innovation is actually gaining traction.

    Nearly 2 billion data points. More than 17,000 digital health innovators. And a healthcare innovation market that is starting to tell a very different story than the headlines might suggest.

    And the data points to an important shift: digital health is growing up.

    A podcast from Humble Ventures
    46 min
  • The Empty Chair Is Not Enough: Craig Lipset on Putting Patients at the Center of Clinical Research
    How lived experience, decentralized trials, nonprofit drug development, and AI could reshape the path from scientific discovery to the patient.

    Clinical research is built to answer extraordinarily complex scientific questions. But for the person deciding whether to participate in a trial, the questions are often much more immediate: How far will I have to travel? Can I take time away from work? Who will care for my children? Will I understand what is happening? And will anyone listen to what I need?

    In our latest episode of The Humble Hang, we sat down with Craig Lipset, a longtime clinical research innovator whose career has spanned academic research centers, biotech, pharmaceutical leadership, patient advocacy, and nonprofit drug development. Formerly the head of clinical innovation at Pfizer, Craig helped pioneer the first fully decentralized clinical trial under an Investigational New Drug application and led an early initiative to return data to research participants. Today, he is co-founder and co-chair of the Digital Trials & Research Alliance (DTRA) and works across a number of initiatives seeking to make drug development more accessible, efficient, and responsive to patients.

    Yet Craig’s perspective is not shaped by professional experience alone. His own patient journey managing a complex diagnosis, navigating health data, and seeking greater flexibility and agency in his own care has deeply informed the innovation he has pursued throughout his career.

    A podcast from Humble Ventures
    50 min
  • Signals Before the Headlines: Why the Future Belongs to the Curious
    A Humble Hang with John Licata - Futures Director and Quantum Lead at ServiceNow

    Most people wait for the future to arrive.

    John Licata spends his career looking for it before everyone else sees it.

    As Director of ServiceNow Futures, John's role isn't simply to predict what's next. It's to identify the subtle signals that eventually become major shifts in technology, business, and society. Those signals might come from a government investment, a customer conversation, a research paper, or even an overlooked news headline. The challenge isn't finding information; we're surrounded by it. The challenge is recognizing which signals actually matter.

    That ability to "look around corners" became one of the central themes of our conversation.

    A podcast from Humble Ventures
    27 min
  • The Human Infrastructure of Healthcare
    In this episode of The Humble Hang, we sit down with Kat McDavitt - President & Founder of Innsena and Founder & CEO of the Zorya Foundation, for an honest conversation about the future of healthcare, the power of community, and why meaningful change starts with people.

    Together, we explore why healthcare has become one of the most complex systems in the world, the role AI can (and can't) play in improving care, the challenges facing rural communities, and how better incentives, not just better technology, can drive lasting transformation.

    Kat also shares the deeply personal story behind the Zorya Foundation, an organization dedicated to supporting women working in healthcare through childcare grants, helping them stay in the workforce while advancing their careers.

    This conversation is a reminder that while policy and technology matter, the future of healthcare will ultimately be shaped by the people willing to show up, listen, and make a difference, one community at a time.

    A podcast from Humble Ventures
    43 min